Movement Alert｜INSILICO Falls 5.44% in Regular Trading, UBS Downgrades Rating to Neutral

Market Focus10-22

On October 22, INSILICO fell 5.44% in Regular Trading, trading at HK$36.4, with turnover of HK$127 million.

The clearest catalyst was a same-day rating action: UBS downgraded INSILICO to Neutral and set a target price of RMB27, which directly pressured sentiment despite recent pipeline and partnership progress.

Earlier this week, the company said it reached an early drug-discovery milestone in its multi-year oncology collaboration with Servier, triggering an undisclosed milestone payment under a partnership valued at up to $888 million, including a $32 million upfront payment and near-term R&D milestones. INSILICO also said it had nominated 11 preclinical candidate compounds in the first 10 months of the year, a record annual pipeline output, underscoring continued activity from its Pharma.AI platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment